Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Cash & Equivalents (2018 - 2025)

Outset Medical (OM) has disclosed Cash & Equivalents for 7 consecutive years, with $172.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 39.34% to $172.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $172.8 million, a 39.34% increase, with the full-year FY2025 number at $172.8 million, up 39.34% from a year prior.
  • Cash & Equivalents was $172.8 million for Q4 2025 at Outset Medical, up from $124.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $307.6 million in Q2 2021 to a low of $35.5 million in Q1 2024.
  • A 5-year average of $121.2 million and a median of $97.2 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 116.81% in 2021, then plummeted 75.36% in 2023.
  • Outset Medical's Cash & Equivalents stood at $215.7 million in 2021, then crashed by 64.51% to $76.5 million in 2022, then dropped by 6.13% to $71.8 million in 2023, then skyrocketed by 72.63% to $124.0 million in 2024, then skyrocketed by 39.34% to $172.8 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Cash & Equivalents are $172.8 million (Q4 2025), $124.0 million (Q4 2024), and $36.6 million (Q3 2024).